Rituximab for intraocular lymphoma

Retina

Volumn 29, Issue 2, 2009, Pages 129-132

  Itty, Sujit ^a   Pulido, Jose S ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBODY; BEVACIZUMAB; CD19 ANTIBODY; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; LYMPHOCYTE SURFACE MARKER; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BRAIN LYMPHOMA; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CATARACT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; CORNEA DISEASE; CORNEAL EPITHELIOPATHY; CYTOLOGY; DELAYED DIAGNOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTRON MICROSCOPE; ELECTROPHYSIOLOGY; ELECTRORETINOGRAM; ENDOPHTHALMITIS; EXTERNAL BEAM RADIOTHERAPY; EYE CANCER; EYE TOXICITY; FOLLICULAR LYMPHOMA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLIA; HISTOLOGY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; KIDNEY TRANSPLANTATION; LARGE CELL LYMPHOMA; LYMPHOCYTE DEPLETION; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MICROSCOPY; MULTIPLE SCLEROSIS; NERVE CELL; NONHODGKIN LYMPHOMA; NONHUMAN; OPHTHALMOSCOPY; OPTIC NERVE; OPTIC NERVE ATROPHY; OVERALL SURVIVAL; PIGMENT EPITHELIUM; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY INTRAOCULAR LYMPHOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; RABBIT; RETINA; RETINA MACULA LUTEA; RETINA MACULOPATHY; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS; VISION; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE; B CELL LYMPHOMA; EDITORIAL; EYE TUMOR; OPTIC NERVE TUMOR; RETINA TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; EYE NEOPLASMS; HUMANS; LYMPHOMA, B-CELL; OPTIC NERVE NEOPLASMS; RETINAL NEOPLASMS; VITREOUS BODY;

EID: 63249103710     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318192f574     Document Type: Review

References (29)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
2. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-174.
3. Anderson DR, Grillo-Lopez A, Varns C, et al. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997;25:705-708.
4. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177- 186.
5. Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 2002;8:836-845.
6. Rodriguez J, Gutierrez A. Pharmacokinetic properties of rituximab. Rev Recent Clin Trials 2008;3:22-30.
7. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235- 242.
8. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
9. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008;59: 237-250.
10. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology-Version 1. 2007. Non-Hodgkin's Lymphomas. Available at: http://www.nccn.org/ preofessionals/physician-gls/PDF/nhl.pdf.
11. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581.
12. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69:95-100.
13. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-251.
14. Gunduz K, Pulido JS, McCannel CA, O'Neill BP. Ocular manifestations and treatment of central nervous system lym-phomas. Neurosurg Focus 2006;21:E9.
15. Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 2007;18: 1851-1855.
16. Baumann MA, Ritch PS, Hande KR, Williams GA, Topping TM, Anderson T. Treatment of intraocular lymphoma with high-dose Ara-C. Cancer 1986;57:1273-1275.
17. de Smet MD, Stark-Vancs V, Kohler DR, et al. Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 1996;121:442-444.
18. Velez G, Yuan P, Sung C, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 2001;119:1518-1524.
19. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-1716.
20. Margolis L, Fraser R, Lichter A, Char DH. The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer 1980;45:688-692.
21. Singh AD, Peereboom DM. Intraocular rituximab. Eye 2007; 21:1453-1454.
22. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9.
23. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
24. Pulido JS, Bakri SJ, Valyi-Nagy T, Shukla D. Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina 2007;27:1071-1073.
25. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262 -269.
26. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162- 164.
27. Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res 2006;82:760-766.
28. Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab. Eye 2007;21:1524-1527.
29. Ohguro N, Hashida N, Tano Y. Effect of intravitreous rituximab injections in patients with ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 2008; 126:1002-1003.